Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19056872 | 0.91 | KCNH2 (0.31) | — | |
| SCHEMBL19056871 | 0.86 | CCR1 (0.35) | — | |
| SCHEMBL19056914 | 0.83 | PRKD3 (0.30) | — | |
| SCHEMBL19056890 | 0.82 | KCNH2 (0.32) | — | |
| SCHEMBL19056880 | 0.81 | SLC40A1 (0.39) | — | |
| SCHEMBL19511225 | 0.81 | AR (0.36) | — | |
| SCHEMBL19511212 | 0.77 | AR (0.35) | — | |
| SCHEMBL19056873 | 0.76 | PDE10A (0.38) | — | |
| SCHEMBL19511293 | 0.74 | AR (0.33) | — | |
| SCHEMBL19511322 | 0.71 | PARP1 (0.32) | PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3187499-B1 | NOVEL GROUP 4 TRANSITION METAL COMPOUND AND USE THEREOF | HANWHA CHEMICAL CORP (KR) | 2019-04-24 | — | — | EP | disclosed |
| US-10160775-B2 | Group 4 transition metal compound and use thereof | HANWHA CHEMICAL CORPORATION (KR) | 2018-12-25 | — | — | US | disclosed |
| US-20170233415-A1 | NOVEL GROUP 4 TRANSITION METAL COMPOUND AND USE THEREOF | HANWHA CHEMICAL CORPORATION (KR) | 2017-08-17 | — | — | US | disclosed |
| EP-3187499-A1 | NOVEL GROUP 4 TRANSITION METAL COMPOUND AND USE THEREOF | Hanwha Chemical Corporation (KR) | 2017-07-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170233415-A1 | NOVEL GROUP 4 TRANSITION METAL COMPOUND AND USE THEREOF | TRPV4, TRPM4, MORF4L1 | PARP1 293/4885 |
| US-10160775-B2 | Group 4 transition metal compound and use thereof | TRPV4, TRPM4, MORF4L1 | PARP1 298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.